However, more than half of CRC display heterogeneous genetic alterations leading to constitutive active EGFR signaling, which negatively affect response to EGFR monoclonal antibodies.[9] Cetuximab is ineffective in CRC patients harboring KRAS or BRAF mutations. The gene discussed is BRAF; the disease is colorectal carcinoma.